
- /
- Supported exchanges
- / US
- / TNDM.NASDAQ
Tandem Diabetes Care Inc (TNDM NASDAQ) stock market data APIs
Tandem Diabetes Care Inc Financial Data Overview
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Tandem Diabetes Care Inc data using free add-ons & libraries
Get Tandem Diabetes Care Inc Fundamental Data
Tandem Diabetes Care Inc Fundamental data includes:
- Net Revenue: 983 M
- EBITDA: -75 068 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-30
- EPS/Forecast: -0.6077
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tandem Diabetes Care Inc News

Abbott Labs stock rating reiterated by Piper Sandler ahead of Q2 earnings
Investing.com - Piper Sandler has reiterated an Overweight rating and $150.00 price target on Abbott Labs (NYSE:ABT), currently trading near its 52-week high at $131.60, ahead of the company’s secon...


Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity
MarketNewsUpdatesNews Commentary NEW YORK, July 15, 2025 /CNW/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-r...

Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sen...

3 Small-Cap Stocks with Open Questions
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small becau...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.